Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Search

Page Path

HOME
Search

Original Article

Effects of different exercise modalities on novel hepatic steatosis indices in overweight women with type 2 diabetes

Ebrahim Banitalebi, Mohammad Faramarzi, Samira Nasiri, Majid Mardaniyan, Vahid Rabiee

Clin Mol Hepatol. 2019;25(3):294-304. Published online May 30, 2019

DOI: https://doi.org/10.3350/cmh.2018.0086

View: 7607 Download: 264 Web of Science: 14 Crossref: 19

The Association of leptin with severity of non-alcoholic fatty liver disease: A population-based study

Laura Rotundo, Alana Persaud, Mirela Feurdean, Sushil Ahlawat, Hyun-seok Kim

Clin Mol Hepatol. 2018;24(4):392-401. Published online August 2, 2018

DOI: https://doi.org/10.3350/cmh.2018.0011

View: 12651 Download: 243 Web of Science: 47 Crossref: 45

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease

Saba Sayari, Hassan Neishaboori, Maryam Jameshorani

Clin Mol Hepatol. 2018;24(3):331-338. Published online June 12, 2018

DOI: https://doi.org/10.3350/cmh.2018.0006

View: 8810 Download: 184 Web of Science: 35 Crossref: 37

Editorial

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?

Yong Kyun Cho

Clin Mol Hepatol. 2018;24(3):299-301. Published online September 7, 2018

DOI: https://doi.org/10.3350/cmh.2018.1006

View: 6046 Download: 106

Review

Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification

Dong Ho Lee

Clin Mol Hepatol. 2017;23(4):290-301. Published online October 10, 2017

DOI: https://doi.org/10.3350/cmh.2017.0042

View: 22029 Download: 490 Web of Science: 100 Crossref: 99

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs

Stephen Caldwell

Clin Mol Hepatol. 2017;23(2):103-108. Published online May 10, 2017

DOI: https://doi.org/10.3350/cmh.2017.0103

View: 12794 Download: 482 Web of Science: 33 Crossref: 33

Original Article

Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea

Eun Haeng Jeong, Dae Won Jun, Yong Kyun Cho, Young Gil Choe, Seungho Ryu, Seung Min Lee, Eun Chul Jang

Clin Mol Hepatol. 2013;19(3):266-272. Published online September 30, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.3.266

View: 9684 Download: 101 Crossref: 67

Editorial

Chasing after novel non-invasive markers to identify advanced fibrosis in NAFLD

Wonseok Kang, Seung Up Kim

Clin Mol Hepatol. 2013;19(3):255-257. Published online September 30, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.3.255

View: 6052 Download: 51 Crossref: 2

Letter to the Editor

Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia

Shuhei Fukunaga, Tomoyuki Nakane, Michita Mukasa, Hidetoshi Takedatsu, Takumi Kawaguchi

Received April 7, 2024 Accepted May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0233 [Epub ahead of print]

View: 704 Download: 47 Crossref: 1

Editorial

Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”

Junjie Yu

Received June 11, 2024 Accepted June 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0443 [Epub ahead of print]

View: 563 Download: 33

Correspondence

The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”

Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li

Received June 24, 2024 Accepted July 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0471 [Epub ahead of print]

View: 446 Download: 37

Editorial

Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease outcomes: A call for culturally sensitive interventions

Jae Hyun Bae

Received July 14, 2024 Accepted July 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0562 [Accepted]

View: 362 Download: 58

Correspondence

Correspondence on Editorial regarding “Towards unification of liver stiffness measurement cutoffs”

Jung Hwan Yu, Seung Up Kim

Received September 18, 2024 Accepted September 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0815 [Accepted]

View: 174 Download: 10

1 | 2 | 3 |

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Impact Factor

14.0
First decision

07 Days

Publication after acceptance

03 Days

*Last 12 months

MOST VIEWED (Last 6 months)

Viewed By 4932	MAFLD: How is it different from NAFLD?
Viewed By 4828	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4726	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4444	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4402	Global incidence and prevalence of nonalcoholic fatty liver disease

+more

MOST CITED (2022-2024)

Cited By 214	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 133	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 117	MAFLD: How is it different from NAFLD?
Cited By 94	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

+more

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051 FAX: +82-2-703-0071 E-mail: kasl@kams.or.kr

COUNTER

TODAY : 230

TOTAL : 2089550